PMID- 17924005
OWN - NLM
STAT- MEDLINE
DCOM- 20080506
LR  - 20190606
IS  - 0074-0276 (Print)
IS  - 0074-0276 (Linking)
VI  - 102
IP  - 6
DP  - 2007 Sep
TI  - Mapping the molecular characteristics of Brazilian human T-cell lymphotropic 
      virus type 1 Env (gp46) and Pol amino acid sequences for vaccine design.
PG  - 741-9
AB  - This study was carried out to evaluate the molecular pattern of all available 
      Brazilian human T-cell lymphotropic virus type 1 Env (n = 15) and Pol (n = 43) 
      nucleotide sequences via epitope prediction, physico-chemical analysis, and 
      protein potential sites identification, giving support to the Brazilian AIDS 
      vaccine program. In 12 previously described peptides of the Env sequences we 
      found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes. 
      The total variation on the amino acid composition was 9 and 17% for human 
      leukocyte antigen (HLA) class I and class II Env epitopes, respectively. After 
      analyzing the Pol sequences, results revealed a total amino acid variation of 
      0.75% for HLA-I and HLA-II epitopes. In 5 of the 12 Env epitopes the 
      physico-chemical analysis demonstrated that the mutations magnified the 
      antigenicity profile. The potential protein domain analysis of Env sequences 
      showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one 
      epitope, and a N-glycosylation site caused by S246Y and V247I mutations in 
      another epitope. Besides, the analysis of selection pressure have found 8 
      positive selected sites (w = 9.59) using the codon-based substitution models and 
      maximum-likelihood methods. These studies underscore the importance of this Env 
      region for the virus fitness, for the host immune response and, therefore, for 
      the development of vaccine candidates.
FAU - Mota-Miranda, Aline Cristina
AU  - Mota-Miranda AC
AD  - Laboratorio Avancado de Saude Publica, Centro de Pesquisa Goncalo Moniz, Fiocruz, 
      Salvador, BA, 40296-610, Brasil. lalcan@cpqgm.fiocruz.br
FAU - de-Oliveira, Tulio
AU  - de-Oliveira T
FAU - Moreau, Domingos Ramon
AU  - Moreau DR
FAU - Bomfim, Catarina
AU  - Bomfim C
FAU - Galvao-Castro, Bernardo
AU  - Galvao-Castro B
FAU - Alcantara, Luiz Carlos Jr
AU  - Alcantara LC Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Mem Inst Oswaldo Cruz
JT  - Memorias do Instituto Oswaldo Cruz
JID - 7502619
RN  - 0 (Gene Products, env)
RN  - 0 (Retroviridae Proteins, Oncogenic)
RN  - 0 (Viral Vaccines)
RN  - 0 (gp46 protein, Human T-cell leukemia virus type I)
SB  - IM
MH  - Amino Acid Sequence
MH  - Base Sequence
MH  - *Drug Design
MH  - *Epitope Mapping
MH  - Gene Products, env/*genetics/immunology
MH  - Human T-lymphotropic virus 1/*genetics/*immunology
MH  - Humans
MH  - Retroviridae Proteins, Oncogenic/*genetics/immunology
MH  - *Viral Vaccines
EDAT- 2007/10/10 09:00
MHDA- 2008/05/07 09:00
CRDT- 2007/10/10 09:00
PHST- 2007/03/30 00:00 [received]
PHST- 2007/07/17 00:00 [accepted]
PHST- 2007/10/10 09:00 [pubmed]
PHST- 2008/05/07 09:00 [medline]
PHST- 2007/10/10 09:00 [entrez]
AID - S0074-02762007000600014 [pii]
AID - 10.1590/s0074-02762007005000089 [doi]
PST - ppublish
SO  - Mem Inst Oswaldo Cruz. 2007 Sep;102(6):741-9. doi: 
      10.1590/s0074-02762007005000089.